Circulating cell-free tumour DNA in the management of cancer

International Journal of Molecular Sciences

Volumn 16, Issue 6, 2015, Pages 14122-14142

  Francis, Glenn ^a,b,c   Stein, Sandra ^a  

^a Genomics For Life   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cell Free dna; Cell Free tumour dna; Colorectal carcinoma; Liquid biopsy; Melanoma; Minimal residual disease; Non Small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CETUXIMAB; CRIZOTINIB; DABRAFENIB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MOLECULAR MARKER; PANITUMUMAB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; TUMOR DNA; UNCLASSIFIED DRUG; VEMURAFENIB; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; COLORECTAL CARCINOMA; ELECTROPHORESIS; GENE MUTATION; GENETIC HETEROGENEITY; HIGH THROUGHPUT SEQUENCING; HUMAN; LIMIT OF DETECTION; MELANOMA; METASTASIS; MINIMAL RESIDUAL DISEASE; NEOPLASM; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE N RAS; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; REVIEW; TUMOR BIOPSY; TUMOR VOLUME; DISEASE COURSE; GENETICS; MUTATION; NEOPLASMS; PATHOLOGY; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; DISEASE PROGRESSION; DNA, NEOPLASM; HUMANS; MUTATION; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING;

EID: 84934933971     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160614122     Document Type: Review

References (105)

1. Allred, D.C.; Harvey, J.M.; Berardo, M.; Clark, G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11, 155–168.
2. Jones, H.B. On a new substance occurring in the urine of a patient with mollities ossium. Philos. Trans. R. Soc. 1848, 138, 55–62.
3. Marzese, D.M.; Hirose, H.; Hoon, D.S. Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Exp. Rev. Mol. Diagn. 2013, 13, 827–844.
4. Long, G.V.; Menzies, A.M.; Nagrial, A.M.; Haydu, L.E.; Hamilton, A.L.; Mann, G.J.; Hughes, T.M.; Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011, 29, 1239–1246.
5. Chapman, P.B., Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507–2516.
6. Flaherty, K.T.; Puzanov, I.; Kim, K.B.; Ribas, A.; McArthur, G.A.; Sosman, J.A.; O’Dwyer, P.J.; Lee, R.J.; Grippo, J.F.; Nolop, K. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363, 809–819.
7. Kwong, L.N.; Davies, M.A. Targeted therapy for melanoma: Rational combinatorial approaches. Oncogene 2014, 33, 1–9.
8. AIHW. Cancer in Australia: An. Overview; AIHW: 2012. Available online: http://www.aihw.gov.au/publication-detail/?id=60129542359 (accessed on 19 June 2015).
9. AIHW. Lung Cancer in Australia An. Overview; AIHW: 2011. Available online: http://www.aihw.gov.au/publication-detail/?id=10737420419 (accessed on 19 June 2015).
10. Luo, S.Y.; Lam, D.C.L. Oncogenic driver mutations in lung cancer. Transl. Respir. Med. 2013, 1, 1–8.
11. Li, T.; Kung, H.J.; Mack, P.C.; Gandara, D.R. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J. Clin. Oncol. 2013, 31, 1039–1049.
12. NCCN. Non-Small Cell. Lung Cancer; NCCN: 2014. p. NSCL-16. Available online: https://www.nccn.org/store/login/login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed on 17 June 2015).
13. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014, 511, 543–550.
14. Roengvoraphoj, M.; Tsongalis, G.J.; Dragnev, K.H.; Rigas, J.R. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat. Rev. 2013, 39, 839–850.
15. Dacic, S. Molecular genetic testing for lung adenocarcinomas: A practical approach to clinically relevant mutations and translocations. J. Clin. Pathol. 2013, 66, 870–874.
16. Yap, T.A.; Popat, S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics. Pers. Med. 2014, 7, 285–295.
17. Lai, Y.; Zhang, Z.; Li, J.; Sun, D.; Zhou, Y.; Jiang, T.; Han, Y.; Huang, L.; Zhu, Y.; Li, X. et al. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int. J. Mol. Sci. 2013, 14, 24549–24559.
18. Tibaldi, C.; Giovannetti, E.; Vasile, E.; Boldrini, L.; Gallegos-Ruiz, M.I.; Bernardini, I.; Incensati, R.; Danesi, R.; Cappuzzo, F.; Peters, G.J. et al. Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J. Thorac. Oncol. 2011, 6, 395–396.
19. Prudkin, L.; Tang, X.; Wistuba, I.I. Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J. Thorac. Oncol. 2009, 4, 139–141.
20. Prudkin, L.; Wistuba, I.I. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann. Diagn. Pathol. 2006, 10, 306–315.
21. Wu, J.Y.; Yu, C.J.; Chang, Y.C.; Yang, C.H.; Shih, J.Y.; Yang, P.C. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin. Cancer Res. 2011, 17, 3812–3821.
22. Cooper, W.A.; Lam, D.C.; O’Toole, S.A.; Minna, J.D. Molecular biology of lung cancer. J. Thorac. Dis. 2013, 5, S479–S490.
23. Wang, H.L.; Lopategui, J.; Amin, M.B.; Patterson, S.D. KRAS mutation testing in human cancers: The pathologistʼs role in the era of personalized medicine. Adv. Anat. Pathol. 2010, 17, 23–32.
24. Allegra, C.J.; Jessup, J.M.; Somerfield, M.R.; Hamilton, S.R.; Hammond, E.H.; Hayes, D.F.; McAllister, P.K.; Morton, R.F.; Schilsky, R.L. American society of clinical oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009, 27, 2091–2096.
25. Van Cutsem, E.; Nordlinger, B.; Cervantes, A. ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann. Oncol. 2010, 21, v93–v97.
26. Aubin, F.; Gill, S.; Burkes, R.; Colwell, B.; Kamel-Reid, S.; Koski, S.; Pollett, A.; Samson, B.; Tehfe, M.; Wong, R. et al. Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer. Curr. Oncol. 2011, 18, 180–184.
27. Sharma, S.G.; Gulley, M.L. BRAF mutation testing in colorectal cancer. Arch. Pathol. Lab. Med. 2010, 134, 1225–1228.
28. Kothari, N.; Schell, M.J.; Teer, J.K.; Yeatman, T.; Shibata, D.; Kim, R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J. Clin. Pathol. 2014, 67, 64–767.
29. Therkildsen, C.; Bergmann, T.K.; Henrichsen-Schnack, T.; Ladelund, S.; Nilbert, M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta. Oncol. 2014, 53, 852–864.
30. Wong, N.A.; Gonzalez, D.; Salto-Tellez, M.; Butler, R.; Diaz-Cano, S.J.; Ilyas, M.; Newman, W.; Shaw, E.; Taniere, P.; Walsh, S.V. RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J. Clin. Pathol. 2014, doi:10.1136/jclinpath-2014-202467.
31. Heinemann, V.; von Weikersthal, L.F.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.E.; Heintges, T.; Lerchenmuller, C.; Kahl, C.; Seipelt, G. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15, 1065–1075.
32. Sclafani, F.; Gonzalez, D.; Cunningham, D.; Hulkki Wilson, S.; Peckitt, C.; Tabernero, J.; Glimelius, B.; Cervantes, A.; Dewdney, A.; Wotherspoon, A. et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J. Natl. Cancer Inst. 2014, 106, dju121.
33. Srinivasan, M.; Sedmak, D.; Jewell, S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 2002, 161, 1961–1971.
34. Do, H.; Wong, S.Q.; Li, J.; Dobrovic, A. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin. Chem. 2013, 59, 1376–1383.
35. Cross, S.S.; Start, R.D.; Smith, J.H. Does delay in fixation affect the number of mitotic figures in processed tissue? J. Clin. Pathol. 1990, 43, 597–599.
36. Cross, S.S.; Start, R.D. Estimating mitotic activity in tumours. Histopathology 1996, 29, 485–488.
37. Kapp, J.R.; Diss, T.; Spicer, J.; Gandy, M.; Schrijver, I.; Jennings, L.J.; Li, M.M.; Tsongalis, G.J.; Gonzalez de Castro, D.; Bridge, J.A. et al. Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: A diagnostic RING trial. J. Clin. Pathol. 2015, 68, 111–118.
38. 38. Dressman, D.; Yan, H.; Traverso, G.; Kinzler, K.W.; Vogelstein, B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl. Acad. Sci. USA 2003, 100, 8817–8822.
39. Marziali, A.; Pel, J.; Bizzotto, D.; Whitehead, L.A. Novel electrophoresis mechanism based on synchronous alternating drag perturbation. Electrophoresis 2005, 26, 82–90.
40. Taly, V.; Pekin, D.; Benhaim, L.; Kotsopoulos, S.K.; Le Corre, D.; Li, X.; Atochin, I.; Link, D.R.; Griffiths, A.D.; Pallier, K. et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 2013, 59, 1722–1731.
41. Sanmamed, M.F.; Fernandez-Landazuri, S.; Rodriguez, C.; Zarate, R.; Lozano, M.D.; Zubiri, L.; Perez-Gracia, J.L.; Martin-Algarra, S.; Gonzalez, A. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. 2015, 61, 297–304.
42. Zhu, G.; Ye, X.; Dong, Z.; Lu, Y.C.; Sun, Y.; Liu, Y.; McCormack, R.; Gu, Y.; Liu, X. Highly sensitive droplet digital PCR method for detection of EGFR activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J. Mol. Diagn. 2015, 17, 265–272.
43. Oshiro, C.; Kagara, N.; Naoi, Y.; Shimoda, M.; Shimomura, A.; Maruyama, N.; Shimazu, K.; Kim, S.J.; Noguchi, S. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res. Treat. 2015, 150, 299–307.
44. Castellanos-Rizaldos, E.; Paweletz, C.; Song, C.; Oxnard, G.R.; Mamon, H.; Janne, P.A.; Makrigiorgos, G.M. Enhanced ratio of signals enables digital mutation scanning for rare allele detection. J. Mol. Diagn. 2015, 17, 284–292.
45. Isobe, K.; Hata, Y.; Tochigi, N.; Kaburaki, K.; Kobayashi, H.; Makino, T.; Otsuka, H.; Ishida, F.; Hirota, N.; Sano, G. et al. Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma. Cancer Genomics Proteomics 2015, 12, 31–37.
46. Higgins, M.J.; Jelovac, D.; Barnathan, E.; Blair, B.; Slater, S.; Powers, P.; Zorzi, J.; Jeter, S.C.; Oliver, G.R.; Fetting, J. et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin. Cancer Res. 2012, 18, 3462–3469.
47. Kamat, A.A.; Baldwin, M.; Urbauer, D.; Dang, D.; Han, L.Y.; Godwin, A.; Karlan, B.Y.; Simpson, J.L.; Gershenson, D.M.; Coleman, R.L. et al. Plasma cell-free DNA in ovarian cancer: An independent prognostic biomarker. Cancer 2010, 116, 1918–1925.
48. Liu, W.; Hu, T.; Chen, Y.; Zhang, X.; Gu, X.; Guan, M. Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection. Mol. Diagn. Ther. 2014, 18, 579–585.
49. Spindler, K.L.; Pallisgaard, N.; Vogelius, I.; Jakobsen, A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin. Cancer Res. 2012, 18, 1177–1185.
50. Board, R.E.; Wardley, A.M.; Dixon, J.M.; Armstrong, A.C.; Howell, S.; Renshaw, L.; Donald, E.; Greystoke, A.; Ranson, M.; Hughes, A. et al. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res. Treat. 2010, 120, 461–467.
51. Xu, J.M.; Liu, X.J.; Ge, F.J.; Lin, L.; Wang, Y.; Sharma, M.R.; Liu, Z.Y.; Tommasi, S.; Paradiso, A. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. J. Exp. Clin. Cancer Res. 2014, 33, 104.
52. Yu, S.; Wu, J.; Xu, S.; Tan, G.; Liu, B.; Feng, J. Modified PNA-PCR method: A convenient and accurate method to screen plasma KRAS mutations of cancer patients. Cancer Biol. Ther. 2012, 13, 314–320.
53. Kim, H.R.; Lee, S.Y.; Hyun, D.S.; Lee, M.K.; Lee, H.K.; Choi, C.M.; Yang, S.H.; Kim, Y.C.; Lee, Y.C.; Kim, S.Y. et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J. Exp. Clin. Cancer Res. 2013, 32, 50.
54. Genomics, B. Performance. 2015; Available online: http://www.borealgenomics.com/technology/performance/ (accessed on 9 June 2015).
55. Forshew, T.; Murtaza, M.; Parkinson, C.; Gale, D.; Tsui, D.W.; Kaper, F.; Dawson, S.J.; Piskorz, A.M.; Jimenez-Linan, M.; Bentley, D. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 2012, 4, 136ra68.
56. Rothe, F.; Laes, J.F.; Lambrechts, D.; Smeets, D.; Vincent, D.; Maetens, M.; Fumagalli, D.; Michiels, S.; Drisis, S.; Moerman, C. et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann. Oncol. 2014, 25, 1959–1965.
57. Huggett, J.F.; Whale, A. Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin. Chem. 2013, 59, 1691–1693.
58. Diehl, F.; Li, M.; He, Y.; Kinzler, K.W.; Vogelstein, B.; Dressman, D. BEAMing: Single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods 2006, 3, 551–559.
59. Sorenson, G.D.; Pribish, D.M.; Valone, F.H.; Memoli, V.A.; Bzik, D.J.; Yao, S.L. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomark. Prev. 1994, 3, 67–71.
60. Vasioukhin, V.; Anker, P.; Maurice, P.; Lyautey, J.; Lederrey, C.; Stroun, M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 1994, 86, 774–779.
61. Dawson, S.J.; Tsui, D.W.; Murtaza, M.; Biggs, H.; Rueda, O.M.; Chin, S.F.; Dunning, M.J.; Gale, D.; Forshew, T.; Mahler-Araujo, B et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 368, 1199–1209.
62. Dowler Nygaard, A.; Spindler, K.L.; Pallisgaard, N.; Andersen, R.F.; Jakobsen, A. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. Oncol. Rep. 2014, 31, 969–974.
63. Kukita, Y.; Uchida, J.; Oba, S.; Nishino, K.; Kumagai, T.; Taniguchi, K.; Okuyama, T.; Imamura, F.; Kato, K. Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS ONE 2013, 8, e81468.
64. Mouliere, F.; El Messaoudi, S.; Gongora, C.; Guedj, A.S.; Robert, B.; del Rio, M.; Molina, F.; Lamy, P.J.; Lopez-Crapez, E.; Mathonnet, M. et al. Circulating cell-free DNA from colorectal cancer patients may reveal high KRAS or BRAF mutation load. Transl. Oncol. 2013, 6, 319–328.
65. Perkins, G.; Yap, T.A.; Pope, L.; Cassidy, A.M.; Dukes, J.P.; Riisnaes, R.; Massard, C.; Cassier, P.A.; Miranda, S.; Clark, J. et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS ONE 2012, 7, e47020.
66. Spindler, K.G.; Appelt, A.L.; Pallisgaard, N.; Andersen, R.F.; Jakobsen, A. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. Br. J. Cancer 2013, 109, 3067–3072.
67. Spindler, K.L.; Sorensen, M.M.; Pallisgaard, N.; Andersen, R.F.; Havelund, B.M.; Ploen, J.; Lassen, U.; Jakobsen, A.K. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma. Acta Oncol. 2013, 52, 963–970.
68. Fleischhacker, M.; Schmidt, B. Circulating nucleic acids (CNAs) and cancer—A survey. Biochim. Biophys. Acta 2007, 1775, 181–232.
69. Schwarzenbach, H.; Stoehlmacher, J.; Pantel, K.; Goekkurt, E. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann. N. Y. Acad. Sci. 2008, 1137, 190–196.
70. Diaz, L.A., Jr.; Williams, R.T.; Wu, J.; Kinde, I.; Hecht, J.R.; Berlin, J.; Allen, B.; Bozic, I.; Reiter, J.G.; Nowak, M.A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486, 537–540.
71. Kauhanen, S.P.; Komar, G.; Seppanen, M.P.; Dean, K.I.; Minn, H.R.; Kajander, S.A.; Rinta-Kiikka, I.; Alanen, K.; Borra, R.J.; Puolakkainen, P.A. et al. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann. Surg. 2009, 250, 957–963.
72. Casali, M.; Froio, A.; Carbonelli, C.; Versari, A. PET/CT imaging in oncology: Exceptions that prove the rule. Case Rep. Oncol. Med. 2013, 2013, 865032.
73. Dondorp, W.; de Wert, G.; Bombard, Y.; Bianchi, D.W.; Bergmann, C.; Borry, P.; Chitty, L.S.; Fellmann, F.; Forzano, F.; Hall, A. et al. Non-invasive prenatal testing for aneuploidy and beyond: Challenges of responsible innovation in prenatal screening. Eur. J. Hum. Genet. 2015, doi:10.1038/ejhg.2015.57.
74. Zhang, H.; Gao, Y.; Jiang, F.; Fu, M.; Yuan, Y.; Guo, Y.; Zhu, Z.; Lin, M.; Liu, Q.; Tian, Z. et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: Clinical experience from 146 958 pregnancies. Ultrasound Obstet. Gynecol. 2015, 45, 530–538.
75. Osborne, C.M.; Hardisty, E.; Devers, P.; Kaiser-Rogers, K.; Hayden, M.A.; Goodnight, W.; Vora, N.L. Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat. Diagn. 2013, 33, 609–611.
76. Hohaus, S. Genomic imbalances in circulating DNA in Hodgkinʼs lymphoma. Lancet Haematol.2015, 2, e48–e49.
77. Vandenberghe, P.; Wlodarska, I.; Tousseyn, T.; Dehaspe, L.; Dierickx, D.; Verheecke, M.; Uyttebroeck, A.; Bechter, O.; Delforge, M.; Vandecaveye, V et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkinʼs lymphoma by sequencing of circulating cell-free DNA: A technical proof-of-principle study. Lancet Haematol. 2015, 2, e55–e65.
78. Knight, M. DNA testing fetus leads moms to their own cancer diagnoses. Genetic Literacy Project 2015; Available online: http://www.geneticliteracyproject.org/2015/03/19/dna-testing-fetus-leads-moms-to-their-own-cancer-diagnoses/ (accessed on 9 June 2015).
79. 79. Diaz, L.A., Jr.; Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. M 2014, 32, 579–586.
80. Lebofsky, R.; Decraene, C.; Bernard, V.; Kamal, M.; Blin, A.; Leroy, Q.; Rio Frio, T.; Pierron, G.; Callens, C.; Bieche, I. et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol. Oncol. 2015, 9, 783–790.
81. McLarty, J.L.; Yeh, C. Circulating cell-free DNA: The blood biopsy in cancer management. MOJ Cell. Sci. Rep. 2015, 2, 0021.
82. Diehl, F.; Schmidt, K.; Choti, M.A.; Romans, K.; Goodman, S.; Li, M.; Thornton, K.; Agrawal, N.; Sokoll, L.; Szabo, S.A.; et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14, 985–990.
83. Dawson, S.J.; Rosenfeld, N.; Caldas, C. Circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 2013, 369, 93–94.
84. Reinert, T.; Scholer, L.V.; Thomsen, R.; Tobiasen, H.; Vang, S.; Nordentoft, I.; Lamy, P.; Kannerup, A.S.; Mortensen, F.V.; Stribolt, K. et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2015, doi:10.1136/gutjnl-2014-308859.
85. Lipson, E.J.; Velculescu, V.E.; Pritchard, T.S.; Sausen, M.; Pardoll, D.M.; Topalian, S.L.; Diaz, L.A., Jr. Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. J. Immunother. Cancer 2014, 2, 42.
86. Tseng, J.Y.; Yang, C.Y.; Liang, S.C.; Liu, R.S.; Jiang, J.K.; Lin, C.H. Dynamic changes in numbers and properties of circulating tumor cells and their potential applications. Cancers 2014, 6, 2369–2386.
87. Turner, N.C.; Garcia-Murillas, I.; Schiavon, G.; Hrebien, S.; Osin, P.; Nerurkar, A.; Kozarewa, I.; Garrido, J.A.; Dowsett, M.; Smith, I.E. Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer. J. Clin. Oncol. 2014, 32, abstr 511.
88. Shinozaki, M.; O’Day, S.J.; Kitago, M.; Amersi, F.; Kuo, C.; Kim, J.; Wang, H.J.; Hoon, D.S. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin. Cancer Res. 2007, 13, 2068–2074.
89. Murtaza, M.; Dawson, S.J.; Tsui, D.W.; Gale, D.; Forshew, T.; Piskorz, A.M.; Parkinson, C.; Chin, S.F.; Kingsbury, Z.; Wong, A.S. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497, 108–112.
90. Bidard, F.C.; Madic, J.; Mariani, P.; Piperno-Neumann, S.; Rampanou, A.; Servois, V.; Cassoux, N.; Desjardins, L.; Milder, M.; Vaucher, I. et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int. J. Cancer 2014, 134, 1207–1213.
91. Oxnard, G.R.; Paweletz, C.P.; Kuang, Y.; Mach, S.L.; O’Connell, A.; Messineo, M.M.; Luke, J.J.; Butaney, M.; Kirschmeier, P.; Jackman, D.M. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014, 20, 1698–1705.
92. Hamakawa, T.; Kukita, Y.; Kurokawa, Y.; Miyazaki, Y.; Takahashi, T.; Yamasaki, M.; Miyata, H.; Nakajima, K.; Taniguchi, K.; Takiguchi, S. et al. Monitoring gastric cancer progression with circulating tumour DNA. Br. J. Cancer 2015, 112, 352–356.
93. Lianos, G.D.; Mangano, A.; Cho, W.C.; Dionigi, G.; Roukos, D.H. Circulating tumor DNA: New horizons for improving cancer treatment. Future Oncol. 2015, 11, 545–548.
94. Wang, Y.; Waters, J.; Leung, M.L.; Unruh, A.; Roh, W.; Shi, X.; Chen, K.; Scheet, P.; Vattathil, S.; Liang, H. et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014, 512, 155–160.
95. Treacy, A.D.; Karamchandani, J.R.; Streutker, C.J.; Grin, A. HER2 genetic heterogeneity in gastric cancer: Evaluation according to the college of American pathologists breast cancer criteria. Appl. Immunohistochem. Mol. Morphol. 2015, doi:10.1097/PAI.0000000000000136.
96. Allison, K.H.; Sledge, G.W. Heterogeneity and cancer. Oncology 2014, 28, 772–778.
97. Kandoth, C.; McLellan, M.D.; Vandin, F.; Ye, K.; Niu, B.; Lu, C.; Xie, M.; Zhang, Q.; McMichael, J.F.; Wyczalkowski, M.A. et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502, 333–339.
98. Steinert, G.; Scholch, S.; Niemietz, T.; Iwata, N.; Garcia, S.A.; Behrens, B.; Voigt, A.; Kloor, M.; Benner, A.; Bork, U. et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014, 74, 1694–1704.
99. De Mattos-Arruda, L.; Weigelt, B.; Cortes, J.; Won, H.H.; Ng, C.K.; Nuciforo, P.; Bidard, F.C.; Aura, C.; Saura, C.; Peg, V. et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle. Ann. Oncol. 2014, 25, 1729–1735.
100. Bozic, I.; Reiter, J.G.; Allen, B.; Antal, T.; Chatterjee, K.; Shah, P.; Moon, Y.S.; Yaqubie, A.; Kelly, N.; Le, D.T. et al. Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2013, 2, e00747.
101. Arnedos, M.; Soria, J.C.; Andre, F.; Tursz, T. Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community? Cancer Treat. Rev. 2014, 40, 1192–1198.
102. Arnedos, M.; Vielh, P.; Soria, J.C.; Andre, F. The genetic complexity of common cancers and the promise of personalized medicine: Is there any hope? J. Pathol. 2014, 232, 274–282.
103. Blair, B.G.; Bardelli, A.; Park, B.H. Somatic alterations as the basis for resistance to targeted therapies. J. Pathol. 2014, 232, 244–254.
104. Beaver, J.A.; Jelovac, D.; Balukrishna, S.; Cochran, R.L.; Croessmann, S.; Zabransky, D.J.; Wong, H.Y.; Valda Toro, P.; Cidado, J.; Blair, B.G. et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin. Cancer Res. 2014, 20, 2643–2650.
105. Kinugasa, H.; Nouso, K.; Miyahara, K.; Morimoto, Y.; Dohi, C.; Tsutsumi, K.; Kato, H.; Matsubara, T.; Okada, H.; Yamamoto, K. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 2015, doi:10.1002/cncr.29364.